Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504131 | 0.90 | SLC6A4 (0.44) | SLC6A2SLC6A4MEN1CYP1A2CYP3A4 | |
| SCHEMBL13644147 | 0.83 | CHRM2 (0.41) | SLC6A2SLC6A4CHRM2AOC3CA12 | |
| SCHEMBL9353842 | 0.80 | CA12 (0.44) | CHRM2AOC3CA12CA1CA2 | |
| SCHEMBL24596957 | 0.80 | HTR7 (0.50) | CYP1A2CYP3A4CHRM2AOC3CA12 | |
| Hydrochloric Acid SCHEMBL9350992 | 0.79 | CA12 (0.43) | CHRM2AOC3CA12CA1CA2 | |
| SCHEMBL15465790 | 0.79 | MEN1 (0.49) | SLC6A2SLC6A4MEN1CYP1A2TSHR | |
| SCHEMBL13705869 | 0.79 | TAAR1 (0.47) | SLC6A2SLC6A4CHRM2AOC3CA12 | |
| SCHEMBL5541296 | 0.79 | CA1 (0.43) | SLC6A2SLC6A4TSHRCHRM2AOC3 | |
| SCHEMBL18043565 | 0.77 | SLC6A2 (0.42) | SLC6A2SLC6A4MEN1KMT2ASIGMAR1 | |
| SCHEMBL8931138 | 0.76 | HTR7 (0.42) | SLC6A2SLC6A4CHRM2AOC3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-05-12 | — | — | US | disclosed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020210308-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-15 | — | — | WO | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2938608-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014100501-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100501-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2287173-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | SLC6A2 322/4885SLC6A4 430/4885MEN1 921/4885 |
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | SLC6A2 3942/4885SLC6A4 4188/4885MEN1 2349/4885 |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | ELOVL3, ELOVL5, SCD5 | SLC6A2 4785/4885SLC6A4 3402/4885MEN1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.